文献速递肝肾功能剂量调整药物相互作用特殊人群用药

克拉屈滨在多发性硬化患者中的群体药代动力学

Population Pharmacokinetics of Cladribine in Patients with Multiple Sclerosis.
PubMed 文献 · Clin Pharmacokinet · 2017-01-01

本研究基于四项临床试验的合并数据,建立克拉屈滨及其主要代谢物2-氯腺嘌呤的群体药代动力学模型,共纳入173例多发性硬化患者、2619个血浆和尿液浓度观测。克拉屈滨呈线性药代动力学,其肾清除与肌酐清除率相关,肾功能不全患者总清除率下降;食物使吸收程度降低11.2%并延迟吸收,与干扰素β-1a合用使非肾清除增加21%。

要点

  • 克拉屈滨肾清除与肌酐清除率相关,轻、中、重度肾功能不全患者总清除率分别下降19%、30%和40%。
  • 食物使克拉屈滨吸收程度降低11.2%并导致吸收延迟。
  • 与干扰素β-1a合用使非肾清除增加21%,总清除率增加11%。

核心结论

  • 克拉屈滨及其代谢物2-氯腺嘌呤在静脉和口服给药后均呈线性药代动力学。
  • 克拉屈滨的肾清除依赖于肌酐清除率,肾功能不全时总清除率下降。

研究设计与样本

  • 基于四项多发性硬化患者临床研究的合并数据集进行群体药代动力学分析,包括三项I期研究(含一项食物效应研究和一项药物相互作用研究)和一项III期临床研究。
  • 共纳入173例多发性硬化患者,获得2619个克拉屈滨和2-氯腺嘌呤的血浆及尿液浓度观测,同时建模。

主要发现

  • 克拉屈滨药代动力学数据最佳由三室模型描述,2-氯腺嘌呤由一室模型描述。
  • 克拉屈滨肾清除与肌酐清除率相关,预测轻(CLCR=65 ml/min)、中(CLCR=40 ml/min)、重度(CLCR=20 ml/min)肾功能不全患者总清除率分别下降19%、30%和40%。
  • 食物使克拉屈滨吸收程度降低11.2%并导致吸收延迟。
  • 与干扰素β-1a合用使非肾清除增加21%,总清除率增加11%。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: The aims of this study were to characterize the concentration-time course of cladribine (CdA) and its main metabolite 2-chloroadenine (CAde), estimate interindividual variability in pharmacokinetics (PK), and identify covariates explaining variability in the PK of CdA. METHODS: This population PK analysis was based on the combined dataset from four clinical studies in patients with multiple sclerosis (MS): three phase I studies, including one food and one drug-drug interaction study, and one phase III clinical study. Plasma and urine concentration data of CdA and CAde were modeled simultaneously. RESULTS: The analysis comprised a total of 2619 CdA and CAde plasma and urine concentration observations from 173 patients with MS who received an intravenous infusion or oral tablet doses of CdA as a single agent or in combination with interferon (IFN) β-1a. CdA PK data were best described by a three-compartment model, while a one-compartment model best described the PK of CAde. CdA renal clearance (CLR) was correlated with creatinine clearance (CLCR), predicting a decrease in the total clearance of 19%, 30% and 40% for patients with mild (CLCR = 65 ml/min), moderate (CLCR = 40 ml/min) and severe (CLCR = 20 ml/min) renal impairment, respectively. Food decreased the extent of CdA absorption by 11.2% and caused an absorption delay. Coadministration with IFNβ-1a was found to increase non-CLR (CLNR) by 21%, resulting in an increase of 11% in total clearance. CONCLUSIONS: Both CdA and CAde displayed linear PK after intravenous and oral administration of CdA, with CdA renal function depending on CLCR. Trial registration number for study 25643: NCT00213135.

来源:Clin Pharmacokinet,查看原文。版权归原作者所有。

引用

  1. Savic RM, Novakovic AM, Ekblom M, et al. Population Pharmacokinetics of Cladribine in Patients with Multiple Sclerosis. Clin Pharmacokinet. 2017. PMID: 28255849. doi:10.1007/s40262-017-0516-6

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。